SRU Biosystems | Company

Management Team &
Board of Directors News Employment Company Overview

Products Overview BIND® Reader • Software • Specifications BIND® Biosensor Download Literature ComBIND™ Microarray Slide

Applications Overview Cell based assays Direct binding small
molecule assays Antibody screening

Management Team
Richard Wagner, PhD President and Chief Executive Officer
	Dr. Wagner was a member of SRU’s science advisory board since 2002, and joined SRU as President and CEO in August, 2007. Prior to this, Dr. Wagner was Executive Vice President of Research at Praecis Pharmaceuticals, Inc., where he was an inventor of the DirectSelect small molecule screening technology that led to the creation of a ten billion compound screening library. Dr. Wagner negotiated collaborations with both Gilead Sciences and GlaxoSmithKline, and the technology and company were both purchased by GlaxoSmithKline in February, 2007. Prior to joining Praecis, Dr. Wagner started operations at Phylos, Inc. in July, 1997 where he held the position of Senior Vice President, Research. At Phylos, Dr. Wagner was an inventor of several technologies, including a class of antibody mimetics (Adnectins), protein microarray applications, and multiplex diagnostic technologies. At Phylos, Dr. Wagner was involved in securing an agreement with Hoechst (now Aventis), as well as a Series B financing. Dr. Wagner also previously worked at Gilead Sciences, Inc., where he was Director, Cell Biology and a member of Gilead's management team. While at Gilead, Dr. Wagner led the development of antisense therapeutics, and was engaged in a collaboration with Glaxo Wellcome. At Gilead, Dr. Wagner was an inventor on several technologies related to antisense therapeutics and delivery methodologies. Dr. Wagner received his B.S. in Biochemistry from Trinity College, and his Ph.D. in Chemistry from Brown University.

Mr. Brant Binder Chief Financial Officer, Founder
	Brant Binder is a founder of SRU Biosystems and has been Chief Financial Officer since its founding in 2000. Mr. Binder comes to SRU Biosystems from Trust Company of the West, where he was a Vice-President responsible for both domestic and international private equity, and helped to raise $500 million in equity commitments. Mr. Binder previously held the position of Vice-President at Bankers Trust Company. Mr. Binder received an M.B.A. from the Sloan School at MIT and a B.S. from Georgetown University's School of Foreign Service.

Dr. Brian Cunningham Chief Technology Officer, Founder
	Brian Cunningham, Ph.D. is a founder of SRU Biosystems and has been Chief Technology Officer since its founding in 2000. Since July 2004, Dr. Cunningham is also Associate Professor in the Department of Electrical and Computer Engineering at the University of Illinois at Urbana-Champaign. His research is focused on application of sub-wavelength optical phenomena and fabrication methods to the development of novel devices and instrumentation in the life sciences. Prior to founding SRU Biosystems, Dr. Cunningham was the Manager of Biomedical Technology at Draper Laboratory (Cambridge, MA), where he established, funded, and directed R&D projects aimed at utilizing defense-related technical capabilities for medical applications. In addition, Dr. Cunningham served as Group Leader for MEMS Sensors at Draper Laboratory, where he directed a group of 30 scientists, engineers, and technicians performing applied research on microfabricated inertial sensors, acoustic sensors, optical switches, microfluidics, and biosensors. Concurrently, he was an Associate Director of the Center for Innovative Minimally Invasive Therapy (CIMIT), a Boston-area medical technology consortium, where he led the Advanced Technology Team on Microsensors. Before working at Draper Laboratory, Dr. Cunningham spent five years at the Raytheon Corporation's Electronic Systems Division. He has 29 journal publications, 5 patents, and 19 patents pending. Dr. Cunningham earned his B.S., M.S., and Ph.D. degrees in Electrical and Computer Engineering at the University of Illinois. Follow this link for more information and a description of the Micro and Nanotechnology lab at the University of Illinois: http://nano.ece.uiuc.edu
Board of Directors
Gordon Binder, Chairman General Partner, Coastview Capital Retired Chairman and CEO, Amgen Inc. Richard Wagner CEO, SRU Biosystems Brant Binder CFO, SRU Biosystems Brian Cunningham CTO, SRU Biosystems